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New DTCA Guidance — Enough to Empower Consumers?
Christopher T. Robertson, J.D., Ph.D.

A

s one of only two countries that permit direct-toconsumer advertising (DTCA) of pharmaceuticals, the United States tasks the Food and Drug Administration (FDA) with regulating that advertising to
ensure that it doesn’t mislead
consumers. When a drug maker
publishes or broadcasts a claim
that its drug has benefits in a particular disease, the FDA requires
it to include information on the
product’s risks as well. Since it’s
not feasible for companies to include all the important information about their products in a
television ad, the FDA requires
them to refer viewers to more
complete information, such as that
in a printed magazine ad. Companies have tended to comply
with this requirement by supplementing colorful, persuasive ads
with one or two pages of dry text
providing the required disclosures,
often simply using language that
the FDA has approved for other
purposes, such as package inserts
for prescribers. But research shows

that most patients who attempt to
read these disclosures find them
difficult to understand, and many
don’t even try to make sense of
them.1 Now, the FDA is in the
process of adjusting its DTCA
rules, aiming to provide greater
assurance that patients receive
due warning of the most significant risks — but its tweaks probably don’t go far enough to really
empower consumers to make
smart decisions about the drugs
they put into their bodies.
This spring, the FDA revised its
guidance for communicating risks
in DTCA, which had been in
“draft” form since 2004.1 The
agency has long recommended the
use of nontechnical language (e.g.,
“drowsiness” rather than “somnolence”) but now also recommends
using an evidence-based format
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for conveying such information.
The FDA’s research supports the
use of a “Drug Facts” box, of the
type that has proven successful
for over-the-counter products,
with familiar headings for “Uses”
and “Warnings.” Alternatively,
companies will be allowed to use
a question-and-answer format, as
some have already been doing.
The draft guidance gives companies additional discretion about
which risks to disclose and how.
Though the FDA continues to insist that any “black-box” warnings
and contraindications be included,
companies will now be able to
omit mention of other adverse
events. The guidance directs companies to include only the “most
serious and the most common”
risks posed by a product. The
idea that it actually helps to give
consumers less of the available
information about a product’s
risks may be counterintuitive, but
the FDA is reasonably concerned
that the recital of extremely rare
risks can distract from, or even
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trivialize, the more significant
disadvantages of a product.
Still, the guidance raises difficult questions about which risks
to exclude, and it’s worrisome
when discretion is given to marketers who have an interest in
downplaying overall risks. For
the industry, such discretion is a
double-edged sword. If a patient
experiences an adverse effect and
files a lawsuit, a civil jury may
find that the advertising was misleading, and a company’s defense
may receive little support from
the FDA’s vague guidance. Some
conservative companies may therefore prefer to continue providing
comprehensive lists, and the new
guidance allows them to do so.
If the FDA is serious about
streamlining disclosures, it may
need to take a stronger approach.
Moreover, the new guidance is
not particularly clear or coherent.
For example, it states that the
“FDA does not intend to object
if a firm does not include ‘each
specific side effect and contraindication,’” but a few pages later,
it says that “information addressing the following should be included: . . . All Contraindications.”1 Admittedly, this is only a
draft document, and clearer guidance may be provided in the final
version. Unfortunately, the FDA
often allows draft documents to
linger for years — the previous
draft guidelines on print advertisements were still not finalized
even after a decade. Even final
guidance documents are technically not binding, but even in draft
form they tend to be very influential in an industry that must
work with the FDA on a daily basis. When the guidance remains
in draft form perpetually, however, it exacerbates the regulatory
ambiguity.
But these concerns are superficial in the context of broader,
1086

more fundamental questions about
risk disclosure as a regulatory
mechanism. From the latter perspective, the guidance represents
a relatively modest reform, which
retains the basic regulatory structure permitting DTCA but requires accompanying disclosures
to mitigate potential harms. The
FDA could instead have issued
highly restrictive guidelines, perhaps cracking down on industry’s use of noncognitive persuasion (think bathtubs in a field of
flowers to suggest the romance
made possible by an erectile-dysfunction drug), which may undermine rational decision making by
patients.2 (Ironically, when the
FDA tried to use its own emotional appeals in the form of graphic
cigarette warnings, industry players objected vociferously.) But the
Supreme Court’s recent First
Amendment jurisprudence —
granting companies rights to free
speech for commercial activities
— would probably constrain such
an aggressive approach. In recent
years, the FDA has sought to
avoid litigation for fear that the
Court might overreact, further
limiting its regulatory ambit.
The Court tends to favor an
approach whereby regulators allow
companies to advertise but require them to append disclosures
to add balance and protect consumer welfare. As legal scholars
Carl Schneider and Omri BenShahar have argued, however, as a
regulatory tool, mandatory “disclosure is a fundamental failure
that cannot be fundamentally
fixed.”3 They cite examples from
myriad domains in which policymakers have reflexively turned to
disclosure as a regulatory tool —
and it has failed. Tweaking the
disclosure regime, as the FDA is
doing here, has proven ineffectual. The regulators of the mortgage industry, in particular, have
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tried to simplify its disclosures
to home buyers, but they’ve had
little success in changing the behavior of consumers or of the
brokers who stand between them
and lenders. Disclosures are no
substitute for regulation of the
products themselves to ensure
that they provide net benefits to
those who consume them, and
they are no substitute for having
well-trained and unconflicted advisors (e.g., prescribers) ensuring
that the product is a good match
for the consumer (e.g., the patient).
If disclosure is to work, as
others have argued, it must be
done right, in a format that’s designed to be usable. As an example of success, Fung et al. cite
the simple, salient, and familiar
“A, B, C” system used to rate restaurants on the basis of public
health inspections, with the results posted prominently by the
door.4 The new FDA guidance is
a move in this direction, at least
if it gives companies more liberty
to construct readable disclosures.
However, even revised disclosures
written by the companies themselves are unlikely to be simple
and candid enough to steer patients away from drugs that are
inappropriate for them. One can
imagine a system that would
grant drugs an “A” rating if they
proved a substantial advance over
the previous standard of care in
treating a serious medical condition, with minimal risks or side
effects. Regrettably, many of the
most widely advertised drugs
would not secure that golden ring.
Unfortunately, the FDA’s guidance will do nothing to help consumers understand whether drugs
really have substantial benefits.
Research has shown that a more
expansive Drug Facts box could
comprehensibly convey data on
the proportion of patients who
actually benefited from the drug
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in key trials and how many had
adverse events.5 If patients and
prescribers used such information to make intelligent choices
about one drug versus another —
or about forgoing medication altogether — it could drive genuine
competition and innovation in
the pharmaceutical
An audio interview
with Dr. Robertson
market. That would
is available at NEJM.org
reflect the sort of
“consumer empowerment” that
free-speech advocates have used
to justify DTCA in the first place.
But such an advance awaits bolder

action by the FDA and the pharmaceutical industry.
Disclosure forms provided by the author
are available with the full text of this article
at NEJM.org.
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The Vernacular of Risk — Rethinking Direct-to-Consumer
Advertising of Pharmaceuticals
Jeremy A. Greene, M.D., Ph.D., and Elizabeth S. Watkins, Ph.D.

A

side from New Zealand, the
United States is the only
country with a strong pharmaceutical regulatory infrastructure
that allows direct-to-consumer
advertising (DTCA) of prescription drugs in print, broadcast,
and electronic media. U.S. consumers are accustomed to fullpage ads in newspapers and
magazines detailing a drug’s
benefits — followed by another
page of fine print in which its
contraindications, risks, and side
effects are spelled out in minute
detail and equally minute print.
That may soon change, however, as the Food and Drug Administration (FDA) moves to enact new regulations regarding risk
communication in DTCA. Earlier
this year, the FDA sought public
comments on new guidance for
pharmaceutical marketers on communicating risks to consumers in
print advertisements. This proposal, which the FDA has kicked
around in one form or another
since 2004, responds to mount-

ing research showing that reprinting highly technical package
inserts in print ads does very
little to communicate risks to
consumers. The goal is to communicate those risks in a new
vernacular.
Instead of reproducing the fine
print meant for physicians and
pharmacists, the FDA proposes
that drug marketers use a new
“consumer brief summary” focused “on the most important
risk information . . . in a way
most likely to be understood by
consumers.” A summary written
in everyday language might take
the form of a Q&A list, for example, or a Drug Facts box like
those on packaging for over-thecounter medicines. Drug marketers are being asked to use popular idiom to communicate with
people with a wide range of literacy levels; to use larger fonts and
more readable formats; and to use
visual elements such as white
space, logos, and color schemes to
highlight the most relevant risks.1
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Public comments on the proposal have focused on the challenges of implementation. How
many risks are too many to
print? How will a manufacturer
— or the FDA — know when
language is too simple, too technical, or pitched “just right” for
average Americans? Missing from
this conversation is a broader
perspective on the vernacular of
risk in pharmaceutical promotion
— as something that is not a
new DTCA-related duty for the
FDA but fundamental to the origins of the category of prescription drugs and their regulation
over the past half-century.
After passage of the 1938 Food,
Drug, and Cosmetic Act, which
established the distinction between prescription-only and overthe-counter drugs, consumers received most information about
the latter through ads and most
about the former from their physician or pharmacist. Indeed, the
category of “prescription-only”
medications enabled industry to
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